Polydex Pharmaceuticals Limited
POLXF · OTC
1/31/2010 | 1/31/2009 | 1/31/2008 | 1/31/2007 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.01 | -0.01 | 0.43 |
| FCF Yield | -82.37% | -26.34% | -73.52% | -11.56% |
| EV / EBITDA | -2.59 | -1.18 | -6.27 | -29.75 |
| Quality | ||||
| ROIC | -26.15% | -34.53% | -10.46% | -6.48% |
| Gross Margin | -2.05% | 0.66% | 6.54% | 12.81% |
| Cash Conversion Ratio | 0.27 | 0.16 | 0.34 | -2.54 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.89% | -9.45% | 2.89% | 0.66% |
| Free Cash Flow Growth | -113.98% | 82.77% | -67.93% | -26.01% |
| Safety | ||||
| Net Debt / EBITDA | -1.52 | -0.41 | -1.31 | 3.48 |
| Interest Coverage | -21.52 | -30.82 | -10.45 | -8.46 |
| Efficiency | ||||
| Inventory Turnover | 3.86 | 4.78 | 3.97 | 4.23 |
| Cash Conversion Cycle | 95.08 | 47.56 | 120.64 | 124.46 |